A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
Details
Age
Adult
Locations
Greeley Campus
Harmony Campus
Medical Center of the Rockies
Poudre Valley Hospital
Principal Investigator
Steven Schuster
Study ID
Protocol Number: 23-0503
More information available at ClinicalTrials.gov: NCT05006716
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers